Randomized study of recombinant human granulocyte colony-stimulating factor after high-dose chemotherapy and autologous bone marrow transplantation for high-risk lymphoid malignancies

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
R A StahelE Platzer

Abstract

The aim of this prospective randomized trial was to examine the efficacy and safety of filgrastim after high-dose chemotherapy and autologous bone marrow transplantation (ABMT). Patients with poor-risk non-Hodgkin's lymphoma or relapsed Hodgkin's disease were treated in a randomized, open-label trial to study the use of filgrastim as an adjunct to high-dose chemotherapy and ABMT. Of 43 assessable patients, 19 were randomized to receive filgrastim by continuous subcutaneous infusion at a dose of 10 micrograms/kg/d, 10 to filgrastim 20 micrograms/kg/d, and 14 to a parallel control group that received no filgrastim after ABMT. For all filgrastim-treated patients analyzed together, the median time to neutrophil recovery > or = 0.5 x 10(9)/L after the day of ABMT was significantly accelerated to 10 days compared with 18 days in control patients (P = .0001). The median number of platelet transfusions was identical in both groups. Clinical parameters, including the median number of days with fever (1 v 4, P = .0418) and neutropenic fever (5 v 13.5, P = .0001) were significantly shorter in the filgrastim than in the control group. The number of days on intravenous antibiotics and duration of hospitalization were also shorter in the tre...Continue Reading

Citations

Feb 1, 1996·Cancer Biotherapy & Radiopharmaceuticals·A Jakubowski, J Gabrilove
Sep 25, 2017·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·David C DaleGary H Lyman
Jan 1, 1997·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·F Offner
Apr 20, 2001·Paediatric Drugs·L M Wagner, W L Furman
Jan 23, 2002·Bone Marrow Transplantation·A A ToorD J Weisdorf
Jun 1, 2002·Bone Marrow Transplantation·J HornedoUNKNOWN SOLTI Group
Oct 1, 2013·Expert Opinion on Investigational Drugs·Jonathan Hoggatt, Louis M Pelus

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.